Future Science Group
Browse
Supplementary Table 1.docx (13.07 kB)

Supplementary Table – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

Download (13.07 kB)
dataset
posted on 2021-11-11, 10:00 authored by Shigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, Taiki Hakozaki, Shingo Kitagawa, Yoshitaka Zenke

Supplementary Table 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

The reasons for dose reduction

Funding

First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

History